Celldex Therapeutics (NASDAQ:CLDX) Stock Price Up 5.2%

Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares rose 5.2% on Tuesday . The company traded as high as $2.26 and last traded at $2.22, approximately 167,920 shares changed hands during trading. A decline of 53% from the average daily volume of 357,724 shares. The stock had previously closed at $2.11.

A number of analysts recently issued reports on the stock. Zacks Investment Research upgraded shares of Celldex Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, May 24th. HC Wainwright set a $19.00 target price on shares of Celldex Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, May 8th. Finally, ValuEngine lowered shares of Celldex Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st.

The stock has a 50-day moving average of $2.41. The stock has a market cap of $32.59 million, a PE ratio of -0.33 and a beta of 3.63. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.33 and a current ratio of 7.33.

Celldex Therapeutics (NASDAQ:CLDX) last announced its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.84) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.17) by $0.33. Celldex Therapeutics had a negative net margin of 942.48% and a negative return on equity of 42.93%. The firm had revenue of $0.72 million for the quarter, compared to analyst estimates of $1.26 million. During the same quarter last year, the business earned ($1.65) earnings per share. Equities analysts forecast that Celldex Therapeutics, Inc. will post -4.8 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Virtu Financial LLC boosted its holdings in shares of Celldex Therapeutics by 72.2% in the 1st quarter. Virtu Financial LLC now owns 25,826 shares of the biopharmaceutical company’s stock valued at $127,000 after purchasing an additional 10,825 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Celldex Therapeutics by 9.0% in the 4th quarter. Geode Capital Management LLC now owns 1,119,913 shares of the biopharmaceutical company’s stock valued at $221,000 after purchasing an additional 92,792 shares during the last quarter. BlackRock Inc. boosted its holdings in shares of Celldex Therapeutics by 12.5% in the 2nd quarter. BlackRock Inc. now owns 340,938 shares of the biopharmaceutical company’s stock valued at $914,000 after purchasing an additional 37,820 shares during the last quarter. HighTower Advisors LLC acquired a new position in shares of Celldex Therapeutics in the 2nd quarter valued at $31,000. Finally, Renaissance Technologies LLC boosted its holdings in shares of Celldex Therapeutics by 67.4% in the 2nd quarter. Renaissance Technologies LLC now owns 912,285 shares of the biopharmaceutical company’s stock valued at $2,445,000 after purchasing an additional 367,179 shares during the last quarter. Hedge funds and other institutional investors own 21.18% of the company’s stock.

About Celldex Therapeutics (NASDAQ:CLDX)

Celldex Therapeutics, Inc engages in the research, development, and commercialization of immunotherapies and other targeted biologics. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379.

Featured Story: What is a good rate of return for a mutual fund?

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.